The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) to Dutch clinical-stage drug ...
3h
Tribune Content Agency on MSNMayo Clinic Q&A: What is Merkel cell carcinoma?I recently heard about a type of skin cancer called Merkel cell carcinoma. I’m not familiar with this condition. Can you explain what it is? Do I need to do anything different to protect myself?
Israel-based clinical-stage company Purple Biotech today announced it is advancing into a Phase II study with NT219 in ...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company ...
NT219, a novel agent designed to overcome tumor resistance to drug therapy, will be evaluated in combination with the standard-of-care head and neck cancer drugs pembrolizumab (Keytruda) or cetuximab ...
Purple Biotech (PPBT) is advancing into a Phase 2 study with NT219 in patients with recurrent/metastatic squamous cell carcinoma of the head ...
A new University of Kentucky Markey Cancer Center study provides important insights for future clinical trials in treating ...
Scottish Medicines Consortium approves Libtayo as second-line treatment for advanced cervical cancer
Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...
Piper Sandler initiated coverage on Merus N.V. (NASDAQ:MRUS), a $2.8 billion market cap biotech company, with an Overweight rating and a price target of $84.00. According to InvestingPro data, the ...
Boston-based Bicara launched in 2021 and is a subsidiary of Indian pharma company Biocon, which provided its seed funding. Bicara is also studying ficerafusp alfa, its lead candidate, in anal cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results